Pharmacovigilance Market Size By Clinical Trial Phase (Preclinical, Phase I, Phase II, Phase III, Phase IV), By Service Provider (In-house, Contract Outsourcing), COVID-19 Impact Analysis, Regional Outlook, Competitive Market Share & Forecast, 2021 – 2027

Report Content

Chapter 1   Methodology

1.1    Methodology

1.2    Market definitions

1.3    Forecast parameters

1.4    Data validation

1.5    Data sources

1.5.1    Secondary

1.5.1.1    Paid sources

1.5.1.2    Unpaid sources

1.5.2    Primary

Chapter 2   Executive Summary

2.1    Pharmacovigilance industry 360⁰ synopsis, 2016 – 2027 (USD Million)

2.1.1    Business trends

2.1.2    Clinical trial phase trends

2.1.3    Service provider trends

2.1.4    Regional trends

Chapter 3   Pharmacovigilance Industry Insights

3.1    Industry segmentation

3.2    Industry landscape, 2016 - 2027

3.3    Industry impact forces

3.3.1    Growth drivers

3.3.1.1    Increase in adoption rate of outsourcing services in Asia Pacific

3.3.1.2    Increasing consumption of drugs in developed regions

3.3.1.3    Rise in adverse drug reactions (ADR) and drug toxicity

3.3.1.4    Increasing acceptance of personalized medicine in developed regions

3.3.1.5    Effective global harmonization practices

3.3.2    Industry pitfalls and challenges

3.3.2.1    Dearth of skilled personnel

3.3.2.2    High risk associated with data security

3.4    Growth potential analysis

3.4.1    By clinical trial phase

3.4.2    By service provider

3.5    COVID-19 impact analysis

3.6    New business models

3.7    Porter’s analysis

3.8    Regulatory landscape

3.9    Pharmacovigilance reporting system

3.10    Competitive landscape

3.10.1    Company matrix analysis

3.11    Pharmacovigilance service landscape

3.12    PESTEL analysis

Chapter 4   Pharmacovigilance Market, By Clinical Trial Phase

4.1    Key segment trends

4.2    Preclinical

4.2.1    Market size, by region, 2016 - 2027 (USD Million)

4.3    Phase I

4.3.1    Market size, by region, 2016 - 2027 (USD Million)

4.4    Phase II

4.4.1    Market size, by region, 2016 - 2027 (USD Million)

4.5    Phase III

4.5.1    Market size, by region, 2016 - 2027 (USD Million)

4.6    Phase IV

4.6.1    Market size, by region, 2016 - 2027 (USD Million)

Chapter 5   Pharmacovigilance Market, By Service Provider

5.1    Key segment trends

5.2    In-house

5.2.1    Market size, by region, 2016 - 2027 (USD Million)

5.3    Contract outsourcing

5.3.1    Market size, by region, 2016 - 2027 (USD Million)

Chapter 6   Pharmacovigilance Market, By Region

6.1    Key regional trends

6.2    North America

6.2.1    Market size, by country, 2016 - 2027 (USD Million)

6.2.2    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.2.3    Market size, by service provider, 2016 - 2027 (USD Million)

6.2.4    U.S.

6.2.4.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.2.4.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.2.5    Canada

6.2.5.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.2.5.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.3    Europe

6.3.1    Market size, by country, 2016 - 2027 (USD Million)

6.3.2    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.3.3    Market size, by service provider, 2016 - 2027 (USD Million)

6.3.4    Germany

6.3.4.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.3.4.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.3.5    UK

6.3.5.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.3.5.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.3.6    Spain

6.3.6.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.3.6.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.3.7    Italy

6.3.7.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.3.7.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.3.8    France

6.3.8.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.3.8.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.4    Asia Pacific

6.4.1    Market size, by country, 2016 - 2027 (USD Million)

6.4.2    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.4.3    Market size, by service provider, 2016 - 2027 (USD Million)

6.4.4    Japan

6.4.4.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.4.4.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.4.5    China

6.4.5.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.4.5.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.4.6    India

6.4.6.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.4.6.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.4.7    Australia

6.4.7.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.4.7.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.5    Latin America

6.5.1    Market size, by country, 2016 - 2027 (USD Million)

6.5.2    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.5.3    Market size, by service provider, 2016 - 2027 (USD Million)

6.5.4    Argentina

6.5.4.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.5.4.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.5.5    Brazil

6.5.5.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.5.5.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.5.6    Mexico

6.5.6.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.5.6.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.6    MEA

6.6.1    Market size, by country, 2016 - 2027 (USD Million)

6.6.2    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.6.3    Market size, by service provider, 2016 - 2027 (USD Million)

6.6.4    South Africa

6.6.4.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.6.4.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.6.5    UAE

6.6.5.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.6.5.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.6.6    Saudi Arabia

6.6.6.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.6.6.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.6.7    Qatar

6.6.7.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.6.7.2    Market size, by service provider, 2016 - 2027 (USD Million)

6.6.8    Israel

6.6.8.1    Market size, by clinical trial phase, 2016 - 2027 (USD Million)

6.6.8.2    Market size, by service provider, 2016 - 2027 (USD Million)

Chapter 7   Company Profiles

7.1    Competitive dashboard

7.2    Clinquest Group B V

7.2.1    Business overview

7.2.2    Financial data

7.2.3    Product landscape

7.2.4    Strategic outlook

7.2.5    SWOT analysis

7.3    Cognizant Technology Solutions Corporation

7.3.1    Business overview

7.3.2    Financial data

7.3.3    Product landscape

7.3.4    Strategic outlook

7.3.5    SWOT analysis

7.4    Ecron Acunova Ltd

7.4.1    Business overview

7.4.2    Financial data

7.4.3    Product landscape

7.4.4    Strategic outlook

7.4.5    SWOT analysis

7.5    Foresight Group International AG

7.5.1    Business overview

7.5.2    Financial data

7.5.3    Product landscape

7.5.4    Strategic outlook

7.5.5    SWOT analysis

7.6    IBM Corporation

7.6.1    Business overview

7.6.2    Financial data

7.6.3    Product landscape

7.6.4    Strategic outlook

7.6.5    SWOT analysis

7.7    ICON plc

7.7.1    Business overview

7.7.2    Financial data

7.7.3    Product landscape

7.7.4    Strategic outlook

7.7.5    SWOT analysis

7.8    iGATE Corporation (Capgemini)

7.8.1    Business overview

7.8.2    Financial data

7.8.3    Product landscape

7.8.4    Strategic outlook

7.8.5    SWOT analysis

7.9    InVentiv Health Clinical

7.9.1    Business overview

7.9.2    Financial data

7.9.3    Product landscape

7.9.4    Strategic outlook

7.9.5    SWOT analysis

7.10    IQVIA (QuintilesIMS)

7.10.1    Business overview

7.10.2    Financial data

7.10.3    Product landscape

7.10.4    Strategic outlook

7.10.5    SWOT analysis

7.11    ITclinical

7.11.1    Business overview

7.11.2    Financial data

7.11.3    Product landscape

7.11.4    Strategic outlook

7.11.5    SWOT analysis

7.12    Laboratory Corporation of America Holdings

7.12.1    Business overview

7.12.2    Financial data

7.12.3    Product landscape

7.12.4    Strategic outlook

7.12.5    SWOT analysis

7.13    Novartis AG

7.13.1    Business overview

7.13.2    Financial data

7.13.3    Product landscape

7.13.4    Strategic outlook

7.13.5    SWOT analysis

7.14    PAREXEL International Corporation

7.14.1    Business overview

7.14.2    Financial data

7.14.3    Product landscape

7.14.4    Strategic outlook

7.14.5    SWOT analysis

7.15    Sanofi

7.15.1    Business overview

7.15.2    Financial data

7.15.3    Product landscape

7.15.4    Strategic outlook

7.15.5    SWOT analysis

7.16    Wipro

7.16.1    Business overview

7.16.2    Financial data

7.16.3    Product landscape

7.16.4    Strategic outlook

7.16.5    SWOT analysis
 

Data Tables

TABLE 1.    Global pharmacovigilance market, 2016 - 2027 (USD Million)

TABLE 2.    Global pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 3.    Global pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 4.    Global pharmacovigilance market, by region, 2016 - 2027 (USD Million)

TABLE 5.    Industry impact forces

TABLE 6.    Pharmacovigilance regulatory initiatives

TABLE 7.    Preclinical market size, by region, 2016 - 2027 (USD Million)

TABLE 8.    Phase I market size, by region, 2016 - 2027 (USD Million)

TABLE 9.    Phase II market size, by region, 2016 - 2027 (USD Million)

TABLE 10.  Phase III market size, by region, 2016 - 2027 (USD Million)

TABLE 11.  Phase IV market size, by region, 2016 - 2027 (USD Million)

TABLE 12.  In-House market size, by region, 2016 - 2027 (USD Million)

TABLE 13.  Contract outsourcing market size, by region, 2016 - 2027 (USD Million)

TABLE 14.  North America pharmacovigilance market, by country, 2016 - 2027 (USD Million)

TABLE 15.  North America pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 16.  North America pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 17.  U.S. pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 18.  U.S. pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 19.  Canada pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 20.  Canada pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 21.  Europe pharmacovigilance market, by country, 2016 - 2027 (USD Million)

TABLE 22.  Europe pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 23.  Europe pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 24.  Germany pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 25.  Germany pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 26.  UK pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 27.  UK pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 28.  Spain pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 29.  Spain pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 30.  Italy pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 31.  Italy pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 32.  France pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 33.  France pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 34.  Asia Pacific pharmacovigilance market, by country, 2016 - 2027 (USD Million)

TABLE 35.  Asia Pacific pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 36.  Asia Pacific pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 37.  Japan pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 38.  Japan pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 39.  China pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 40.  China pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 41.  India pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 42.  India pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 43.  Australia pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 44.  Australia pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 45.  Latin America pharmacovigilance market, by country, 2016 - 2027 (USD Million)

TABLE 46.  Latin America pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 47.  Latin America pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 48.  Argentina pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 49.  Argentina pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 50.  Brazil pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 51.  Brazil pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 52.  Mexico pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 53.  Mexico pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 54.  MEA pharmacovigilance market, by country, 2016 - 2027 (USD Million)

TABLE 55.  MEA pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 56.  MEA pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 57.  South Africa pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 58.  South Africa pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 59.  UAE pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 60.  UAE pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 61.  Saudi Arabia pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 62.  Saudi Arabia pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 63.  Qatar pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 64.  Qatar pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)

TABLE 65.  Israel pharmacovigilance market, by clinical trial phase, 2016 - 2027 (USD Million)

TABLE 66.  Israel pharmacovigilance market, by service provider, 2016 - 2027 (USD Million)
 

Charts & Figures

FIG 1.   Pharmacovigilance industry 360⁰ synopsis, 2016 - 2027

FIG 2.   Industry segmentation

FIG 3.   Global pharmacovigilance market size, 2016 - 2027 (USD Million)

FIG 4.   Growth potential analysis, by clinical trial phase

FIG 5.   Growth potential analysis, by service provider

FIG 6.   Types of pharmacovigilance outsourcing vendors

FIG 7.   Porter’s analysis

FIG 8.   Company matrix analysis

FIG 9.   PESTEL analysis

FIG 10. Key segmental trends, by clinical trial phase

FIG 11. Key segmental trends, by service provider

FIG 12. Key regional trends

FIG 13. Competitive dashboard